CN110772528A

CN110772528A - Application of iris polysaccharide in preparation of medicine for preventing and treating leptospirosis

Info

Publication number: CN110772528A
Application number: CN201911265637.2A
Authority: CN
Inventors: 曹永国; 宋宁; 吴殿君; 张文龙; 谢旭峰; 吕天宝; 王佳琪; 丁越; 张石磊
Original assignee: Jilin University
Current assignee: Jilin University
Priority date: 2019-12-11
Filing date: 2019-12-11
Publication date: 2020-02-11
Anticipated expiration: 2039-12-11
Also published as: CN110772528B

Abstract

The invention provides an application of tectori polysaccharide in preparing a medicament for preventing and treating leptospirosis, which adopts a standard substance of astragalus polysaccharide to inject the astragalus polysaccharide into golden yellow mice sensitive to leptospirosis in advance at a dose of 50mg/kg, can effectively control the infection of leptospirosis after infecting leptospirosis of 2X108/ml, and has a survival rate of 100 percent. The invention expands the medicinal range of the astragalus polysaccharide and provides a basis for developing new application of the iris polysaccharide.

Description

Application of iris polysaccharide in preparation of medicine for preventing and treating leptospirosis

Technical Field

Leptospirosis (Leptospirosis) is a worldwide common zoonotic disease, called Leptospirosis for short, that is associated with occupational or living contacts and with exposure to leptospira, and is highly prevalent in flood-prone areas, and is particularly widespread in developing countries and tropical regions. The disease is susceptible to human and livestock, and the clinical manifestations after infection are various, so that diagnosis is not easy. The pathogen of the leptospirosis can continuously exist in the host, further spread to pollute the environment, infect other people and animals, and cause serious harm. Currently, the methods for preventing and treating leptospira are the injection of vaccines and the use of antibiotics.

Iris, namely Indian iris, fanglauca herbs, rhizoma anemarrhenae and the like, are originally produced in China and Japan, are perennial herbaceous plants with bitter, pungent and mild properties, and are common Chinese herbal medicines in China. Has the main functions of promoting blood circulation to remove blood stasis, dispelling wind and promoting diuresis, detoxifying and removing food retention. Can be used for treating traumatic injury, rheumatalgia, sore throat, food stagnation, abdominal distention, malaria, carbuncle, furuncle, toxic swelling, and traumatic hemorrhage. The research on the iris polysaccharide in China is less, and the iris lactuca polysaccharide is especially fresh in terms of preventing and treating leptospira.

Background

The invention discloses application of tectori polysaccharide in preparation of a medicament for preventing and treating leptospirosis, provides new medical application of tectori polysaccharide, and belongs to the technical field of medicines.

Disclosure of Invention

The invention aims to provide application of tectori polysaccharide as a medicament in preparing medicaments for preventing and treating leptospirosis, including the prevention of leptospirosis and the treatment after infection. The application of the tectoridin can reduce the abuse of antibiotics and can also effectively prevent and control leptospira outbreak.

The invention aims to provide application of tectori polysaccharide as a medicament in preparing medicaments for preventing and treating leptospirosis, including the prevention of leptospirosis and treatment after infection.

The polysaccharide of the iris of the invention is used as a medicament for preventing and treating leptospirosis.

The iris polysaccharide substance is used as a medicine for preventing and treating leptospira, and is suitable for any pharmaceutically acceptable carrier.

The pharmaceutical preparation is standard liquid preparation of tectorigenin, and the dosage of the pharmaceutical preparation is 5mg/ml by dissolving and diluting tectorigenin powder with normal saline, namely 10 mg/kg.

The tectorial polysaccharide can effectively control the infection of leptospira, reduce the inflammatory reaction of each organ and improve the survival rate of golden hamster to 100 percent.

The invention has the positive effects that:

provides a new medical application of the tectorigenin for preparing a medicine for preventing and treating leptospira; carrying out secondary development on the pharmacological action of the compound; the medicinal range of the iris polysaccharide is expanded; the invention can effectively reduce the use of antibiotics when treating and preventing leptospirosis, can also effectively prevent and control leptospirosis during outbreak, and has great effect on the healthy development of animal husbandry.

Description of the drawings:

FIG. 1 is a graph of the resistance of golden hamsters to leptospira infection following injection of tectori polysaccharide;

FIG. 2 is a graph of the scavenging effect of tectorigenin on leptospira within the body;

FIG. 3 shows the protective effect of tectorigenin on the major organs of golden hamster;

FIG. 4 shows that tectorigenin causes the expression level of important inflammatory factors in the body.

The specific implementation mode is as follows:

the present invention is further illustrated by the following examples, which do not limit the present invention in any way, and any modifications or changes that can be easily made by a person skilled in the art to the present invention will fall within the scope of the claims of the present invention without departing from the technical solution of the present invention.

Example 1

The polysaccharide extract of Iris tectorum can be used as medicine for preventing and treating leptospirosis.

Example 2

The tectori polysaccharide used as the medicine for preventing and treating leptospira is suitable for any pharmaceutically acceptable carrier.

Example 3

The pharmaceutical preparation is an iris polysaccharide standard liquid preparation, and the iris polysaccharide powder is dissolved and diluted by normal saline according to dosage.

Example 4

Test example 1

Application of tectorum polysaccharide in preventing leptospira infection

Experimental drugs:

the standard substance of iris polysaccharide was diluted with physiological saline at 5mg/ml and injected subcutaneously at a dose of 50mg/kg based on the body weight of golden hamster.

The experimental method comprises the following steps:

the experiment was divided into two groups, i.e., an experimental group and a control group, each of eight four-week-old golden hamster. The experimental group was injected with irises per dose according to body weight one week before infection, and the control group was injected with normal saline. One week later, 2 × 108 leptospira were intraperitoneally injected. And observing the survival rate.

The experimental results are as follows:

referring to fig. 1, the survival rate of the experimental group injected with iris polysaccharide was 50%, while all of the golden yellow mice of the control group died. Indicating that the tectorigenin can effectively prevent the infection of leptospira.

Test example 2

Iris polysaccharide has effect in clearing leptospira in organism

The experimental method comprises the following steps:

the golden hamster of the control group and the experimental group in experimental example 1 was sampled, the liver, kidney and lung of each group of golden hamster were collected, DNA extraction of leptospira in the tissue was performed, and then a fluorescent quantitative PCR experiment was performed to analyze the load of leptospira in each organ of golden hamster.

The experimental results are as follows:

referring to fig. 2, compared to the control group injected with physiological saline only, the mice injected with tectori polysaccharide had a significant decrease in the leptospira loading in liver, kidney and lung.

Test example 3

The control and experimental groups of golden hamster of test example 1 were sampled for liver, kidney and lung, RNA was extracted, and then, fluorescent quantitative PCR was performed to analyze the expression of Tlr2, Tlr4, IL-1 β and iNOS in the respective organs of golden hamster 2 days and 5 days after challenge.

The experimental results are as follows:

referring to FIG. 3, the expression of TLR2 mRNA in liver and kidney was significantly higher at 2dpi and lower at 5dpi in the test group injected with Iridan compared to the control group, however, the expression of TLR2 mRNA in lung was significantly reduced in the test group at the same time, the expression of TLR4 mRNA was reduced or induced to be reduced at 2dpi and significantly reduced at 5dpi in the test group, and the expression of IL-1 β was higher at 2dpi and lower at 5dpi in all organs compared to the control group injected with Iridan, these results indicate that Iridan caused the expression of a large amount of TLR2 and IL-1 β mRNA in organs at 2dpi and the reduction of expression of TLR2, TLR4 and IL-1 β at 5dpi, and that Iridan caused inflammatory storm to reach and prematurely reduce at 5dpi, thus exerting a golden mouse protective effect.

Test example 4

The golden hamster of the control group and the golden hamster of the experimental group in test example 1 was sampled for liver, kidney and lung to prepare pathological sections, and HE staining was performed. Observation was performed under an optical microscope at 200 times.

The experimental results are as follows:

referring to fig. 4, the liver, kidney and lung of the golden hamster of the control group all had bleeding and inflammatory lesions of different degrees, while the pathological changes of the liver, kidney and lung of the golden hamster of the experimental group were not particularly obvious and had substantially no bleeding points and inflammatory lesions.

Claims

1. The medical application of iris polysaccharide in preparing medicines for preventing and treating leptospira disease is provided.

2. The tectori polysaccharide used as the medicine for preventing and treating leptospira is suitable for any pharmaceutically acceptable carrier.

3. The pharmaceutical preparation is a liquid preparation of astragalus polysaccharide standard substance, β -glucan powder is dissolved and diluted by normal saline according to the dosage, 5mg/ml, and the dosage of β -glucan is 10 mg/kg.